

Ahmad R. Khosropour* and Jalil Noei


Catalysis Division, Department of Chemistry, University of Isfahan, Isfahan 81746-73441, Iran

*E-mail: khosropour@chem.ui.ac.ir

Received April 28, 2009

DOI 10.1002/jhet.261

Published online 6 October 2010 in Wiley Online Library (wileyonlinelibrary.com).



An efficient and practical procedure for direct synthesis of 3,5-diaryl-1,2,4-thiadiazoles by thioamides with 2,4,6-trichloro-1,3,5-triazine (TCT) and dimethylsulfoxide using 1-butyl-3-methylimidazolium tetrafluoroborate as an eco-friendly reaction medium under ambient temperature is described. This protocol can be considered as a new procedure for 3,5-diaryl-1,2,4-thiadiazoles synthesis.

J. Heterocyclic Chem., **48**, 226 (2011).

INTRODUCTION

1,2,4-Thiadiazole nucleus constitutes the core units of many natural products [1]. Although, currently, the only commercial 1,2,4-thiadiazole drug is the antibiotic cefozopram [2], there are a number of synthetic products related to this system with a broad range of biological activities concerning central nervous system (CNS) [3], G-protein coupled receptors [4], inflammation [5], cardiovascular system [6], or antibiotic activity [7]. The antioxidant and muscarinic receptor binding properties of a family of 1,2,4-thiadiazole derivatives has also shown acetylcholinesterase inhibitory activity [3]. A number of derivatives were described as the first non-ATP competitive glycogen synthase kinase 3 β inhibitors [8]. Also, the properties of 1,2,4-thiadiazoles as thiol trapping agents have been recently reviewed [9].


Traditional methods for the synthesis of 3,5-diaryl-1,2,4-thiadiazoles limited to the oxidative dimerization reaction of thioamides with 1-methyl pyridinium chloride, benzoyl chloride, or acetyl chloride in chlorinated organic solvents [10]. Recently, these compounds have also been prepared by stoichiometric amount of PhI(OAc)₂ at 70°C [11]. However, these methods are not quite satisfactory in view of using large excess of reagents, long reaction times, harsh reaction conditions, and also involvement of toxic solvents such as acetonitrile or dichloromethane. Hence, there is a need to develop a convenient, simple, rapid, and environmentally friendly method for the synthesis of these important heterocyclic compounds.

RESULTS AND DISCUSSION

In recent years, 2,4,6-trichloro-1,3,5-triazine (TCT) has invoked enormous interest in various organic transformations [12]. Moreover, ionic liquids (ILs) have emerged extensively as a novel eco-friendly reaction media for many organic syntheses [13]. In such perspective, in the combination with our recent lies on the design of new synthetic methodologies [14] and development of useful tactics and strategies for the synthesis of heterocyclic compounds [15], especially in ILs [16], we report, herein, a novel and efficient procedure using of TCT-DMSO as a new promoter system in [bmim]BF₄ for direct synthesis of 3,5-diaryl-1,2,4-thiadiazoles from arylthioamids (Scheme 1).

To the best of our knowledge; there is no report on the oxidative dimerization reaction with TCT-DMSO in ionic liquid. At the onset of this work, to explore the scope of this method, we used thiobenzamide as a model, and the role of various conditions on the reaction system was investigated (Table 1). We found that the optima ratio of thioamide/TCT/DMSO is about 1:0.3:1 (Table 1, entry 5). Further investigations revealed that reducing the loading of TCT to 0.25 equiv gave the desired product in a lower yield of 79% (Table 1, entry 4). The use of 1 equiv of DMSO was also found to be necessary for this transformation to proceed smoothly; when DMSO was reduced to 0.9 equiv, a slightly lower product yield of 81% was afforded (Table 1, entry 6).

To determine the most appropriate solvent, the reaction was examined using different ILs and also using



traditional solvents such as ethanol, acetonitrile, and chloroform. The results are summarized in Table 1. Choosing an appropriate solvent is of crucial importance for successful synthesis. [bmim]BF₄ and [bmim]OTf were the best solvents in terms of yields (Table 1, entries 5 and 7). However, [bmim]BF₄ as water could be used for the work-up. Interestingly, we observed that combination of TCT-DMSO in [bmim]BF₄ is essential for this transformation that attempts to carry out the reactions, in the absence of each of these almost did not yield the product. Another important factor was the reaction temperature.

The experiments were run from 0 to 40°C. We found that those conducted at room temperature (23–25°C) afforded almost quantitative yields, whereas at 40°C some by-products were observed. The experimental procedure for this transformation is remarkably straightforward and does not require the use of toxic organic solvents or inert atmospheres. The structures of the products were established by ¹H NMR, ¹³C NMR, IR, and mass spectrum. The use of these optimal experimental conditions to the reactions of different arylthioamides containing both electron-donating and electron-withdrawing groups in the aromatic rings was found to undergo the conversion smoothly (Table 2, entries a–j). The reaction proceeded at room temperature, and the products were formed within 10–12 min in excellent

Table 1
Optimization of conditions in the synthesis of 3,5-diphenyl-1,2,4-thiadiazole.

Entry	TCT:DMSO equiv	Solvent ^a	Time (min)	Yield (%) ^b
1	0.1:1	[bmim]BF ₄	10	18
2	0.15:1	[bmim]BF ₄	10	54
3	0.2:1	[bmim]BF ₄	10	75
4	0.25:1	[bmim]BF ₄	10	79
5	0.3:1	[bmim]BF ₄	10	96
6	0.3:0.9	[bmim]BF ₄	10	81
7	0.3:1	[bmim]OTf	10	95
8	0.3:1	[bmim]PF ₆	10	42
9	0.3:1	PYRTFSI ^c	10	60
10	0.3:0	[bmim]BF ₄	60	0
11	0.3:1	CH ₃ CN	60	65
12	0.3:1	EtOH	60	50
13	0.3:1	CHCl ₃	60	45

^a 2 mL.

^b Isolated yield.

^c *N*-butyl-*N*-methylpyrrolidinium bi(trifluoromethanesulfonyl)imide.

Table 2

Synthesis of 3,5-diphenyl-1,2,4-thiadiazoles through oxidation condensation reaction promoted with TCT-DMSO in [bmim]BF₄ as a room temperature ionic liquid.

Entry	Ar	Time (min)	Yield (%) ^a
a	C ₆ H ₅	10	96
b	4-FC ₆ H ₄	10	94
c	4-ClC ₆ H ₄	10	95
d	4-BrC ₆ H ₄	10	93
e	3-BrC ₆ H ₄	10	93
f	2,4-Cl ₂ C ₆ H ₃	10	92
g	3-ClC ₆ H ₄	10	94
h	2-ClC ₆ H ₄	10	90
i	4-CH ₃ OC ₆ H ₄	10	93
j	4-BnOC ₆ H ₄	10	90
k	2-furyl	12	91


^a Yields refer to isolated pure products.

yields. Acid sensitive thioamides such as 2-furylthioamide also formed the corresponding thiadiazole quantitatively (Table 2, entry k).

Based on the earlier experimental results and the literature [10], we propose a plausible reaction pathway, as shown in Scheme 2.

Addition of DMSO to TCT in [bmim]BF₄ causes the oxidation of thioamide to *N*-chlorothioamide. Nucleophilic attack by sulfur of another molecule of thioamide to *N*-chlorothioamide gives the intermediate (A) that on further rapid oxidation gives the product.

In conclusion, we have presented a new, mild, efficient, and convenient method for the preparation of 3,5-diaryl-1,2,4-thiadiazoles through oxidative dimerization using combination of TCT and DMSO in ionic liquid. Moreover, in comparison to the previous methods, this protocol design a unique rut for the efficient synthesis of 3,5-diphenyl-1,2,4-thiadiazoles at room temperature using a novel promoter system. Also, we have shown



that the method is tolerant to a variety of functional groups. By using this protocol, we synthesized target molecules in excellent yields. The details of synthetic applications of this methodology are being further studied in our laboratory.

EXPERIMENTAL

General procedure for the synthesis of 3,5-diaryl-1,2,4-thiadiazoles by thioamides promoted with TCT and dimethylsulfoxide in [bmim]BF₄. To a stirred solution of arylthioamide (1 mmol) in [bmim]BF₄ (2 mL) at r.t. was added TCT (0.0554 g, 0.3 mmol) and DMSO (0.078 g, 1 mmol). The reaction mixture was stirred magnetically at room temperature for the specified time (see Table 2) until arylthioamide was completely disappeared (the progress of the reaction was followed by TLC). When the reaction was completed, quenched with ice water (10 mL) and stirred at room temperature for 10 min. The above mixture was extracted with ethyl acetate (3 × 5 mL), and the organic layers were combined and washed with brine. After dryness and concentration in vacuo, the residue was chromatographed on silica gel (*n*-heptane/ethyl acetate as eluent) to afford the pure product in 90–96% yield.

3,5-Diphenyl-[1,2,4]thiadiazole. Solid, mp 81–83°C; ¹H NMR (500 MHz, CDCl₃) δ 8.41 (br s, 2 H), 8.07 (br s, 2 H), 7.54–7.50 (m, 6 H). ¹³C NMR (125 MHz, CDCl₃) δ 182.1, 174.5, 133.5, 130.9, 130.9, 130.6, 131.1, 129.2, 129.2, 128.7, 127.5, 127.5, 129.2, 129.2. Anal. Calcd. For C₁₄H₁₀N₂S: C, 70.56; H, 4.23; N, 11.76; S, 13.46. Found: C, 70.60; H, 4.20; N, 11.77; S, 13.43.

3,5-Bis(4-methoxyphenyl)[1,2,4]thiadiazole. Solid, mp 128–130°C; ¹H NMR (500 MHz, CDCl₃) δ 8.32 (d, *J* = 8.8 Hz, 2 H), 7.99 (d, *J* = 8.8 Hz, 2 H), 7.01 (m, 4 H), 3.90 (s, 3 H), 3.89 (s, 3 H). ¹³C NMR (125 MHz, CDCl₃) δ 180.1, 171.5, 162.8, 160.1, 140.3, 140.4, 138.2, 138.3, 128.3, 127.6, 114.6, 114.4, 111.8, 111.6, 59.7, 59.6. Anal. Calcd. For C₁₆H₁₆N₂O₂S: C, 63.98; H, 5.37; N, 9.33; S, 10.67. Found: C, 63.91; H, 5.39; N, 9.30; S, 10.71.

3,5-Bis(4-benzyloxyphenyl)[1,2,4]thiadiazole. Solid, mp 154–157°C; ¹H NMR (500 MHz, CDCl₃) δ 7.59 (d, *J* = 8.6 Hz, 4 H), 7.42–7.36 (m, 10 H), 7.02 (d, *J* = 8.7 Hz, 4 H), 5.12 (s, 4 H). ¹³C NMR (125 MHz, CDCl₃) δ 180.2, 171.6, 162.1, 162.1, 162.0, 162.0, 134.2, 134.1, 133.4, 133.4, 133.3, 133.2, 132.2, 132.1, 131.6, 128.7, 126.8, 126.8, 123.9, 123.9, 123.8, 123.8, 123.0, 123.0, 122.9, 129.9. Anal. Calcd. For C₂₆H₁₈N₂O₂S: C, 73.92; H, 4.29; N, 6.63; S, 7.59. Found: C, 73.89; H, 4.31; N, 6.65; S, 7.57.

3,5-Di(2-furyl)-[1,2,4]thiadiazole. Solid, mp 88–90°C; ¹H NMR (500 MHz, CDCl₃) δ 7.93 (d, *J* = 3.5 Hz, 1 H), 7.70 (d, *J* = 3.7 Hz, 1 H), 7.58 (d, *J* = 5.1 Hz, 1 H), 7.45 (d, *J* = 5 Hz, 1 H), 7.18–7.13 (m, 2 H). ¹³C NMR (125 MHz, CDCl₃) δ 185.1, 170.4, 159.0, 151.3, 151.1, 147.9, 117.1, 117.0, 117.0, 112.1. Anal. Calcd. For C₁₀H₆N₂O₂S: C, 55.03; H, 2.77; N, 12.84; S, 17.71. Found: C, 55.32; H, 2.41; N, 12.65; S, 17.62.

3,5-Bis(4-chlorophenyl)[1,2,4]thiadiazole. Solid, mp 146–148°C; ¹H NMR (500 MHz, CDCl₃) δ 8.32 (d, *J* = 8.5 Hz, 2 H), 7.99 (d, *J* = 8.5 Hz, 2 H), 7.51 (d, *J* = 8.5 Hz, 2 H), 7.48 (d, *J* = 8.5 Hz, 2 H). ¹³C NMR (125 MHz, CDCl₃) δ 187.0, 173.1, 133.3, 133.0, 132.7, 132.5, 132.1, 132.0, 129.8, 129.4, 128.8, 126.6, 125.0. Anal. Calcd. For C₁₄H₈Cl₂N₂S: C, 54.74;

H, 2.62; N, 9.12; S, 10.44. Found: C, 54.60; H, 2.59; N, 9.04; S, 10.29.

3,5-Bis(3-chlorophenyl)[1,2,4]thiadiazole. Solid, mp 123–125°C; ¹H NMR (500 MHz, CDCl₃) δ 8.39 (d, *J* = 1.6 Hz, 1 H), 8.27 (dd, *J* = 6.9 Hz, 1 H), 8.07 (d, *J* = 1.7 Hz, 1 H), 7.89 (d, *J* = 7.6 Hz, 1 H), 7.54–7.42 (m, 4 H). ¹³C NMR (125 MHz, CDCl₃) δ 186.9, 172.5, 135.5, 134.8, 134.2, 132.0, 131.9, 130.6, 130.5, 130.0, 128.5, 127.3, 126.4, 125.6. Anal. Calcd. For C₁₄H₈Cl₂N₂S: C, 54.74; H, 2.62; N, 9.12; S, 10.44. Found: C, 54.51; H, 2.62; N, 9.15; S, 10.25.

3,5-Bis(2-chlorophenyl)[1,2,4]thiadiazole. Solid, mp 85–86°C; ¹H NMR (500 MHz, CDCl₃) δ 8.65 (m, 1 H), 8.05 (m, 1 H), 7.60–7.55 (m, 2 H), 7.48–7.46 (m, 2 H), 7.42–7.40 (m, 2 H); ¹³C NMR (125 MHz, CDCl₃) δ 183.0, 173.2, 133.8, 133.3, 132.2, 132.1, 132.0, 130.9, 130.7, 130.6, 130.4, 129.6, 127.4, 126.7. Anal. Calcd. For C₁₄H₈Cl₂N₂S: C, 54.74; H, 2.62; N, 9.12; S, 10.44. Found: C, 54.42; H, 2.82; N, 9.35; S, 10.51.

3,5-Bis(2,4-dichlorophenyl)[1,2,4]thiadiazole. Solid; mp 132–134°C. ¹H NMR (500 MHz, CDCl₃): δ = 7.39 (1 H, dd, *J* = 8.2 Hz), 7.46 (1 H, dd, *J* = 8.4 Hz), 7.58 (1 H, d, *J* = 2.1 Hz), 7.63 (1 H, d, *J* = 2.1 Hz), 8.04 (1 H, d, *J* = 8.4 Hz), 8.57 (1 H, d, *J* = 8.6 Hz). ¹³C NMR (125 MHz, CDCl₃): δ = 127.1, 128.1, 129.7, 130.2, 130.8, 131.4, 133.1, 134.1, 134.3, 136.3, 136.4, 137.9, 173.2, 182.2. Anal. Calcd. For C₁₄H₆Cl₄N₂S: C, 44.71; H, 1.61; N, 7.45; S, 8.52. Found: C, 44.36; H, 1.82; N, 7.33; S, 8.75.

3,5-Bis(4-bromophenyl)[1,2,4]thiadiazole. Solid, mp 149–154°C; ¹H NMR (500 MHz, CDCl₃) δ 8.24 (d, *J* = 8.5 Hz, 2 H), 7.90 (dd, *J* = 6.6 Hz, 2 H), 7.66 (dd, *J* = 6.7 Hz, 2 H), 7.63 (dd, *J* = 6.7 Hz, 2 H); ¹³C NMR (125 MHz, CDCl₃) δ 187.1, 173.2, 132.8, 132.5, 132.3, 132.2, 131.9, 131.6, 129.8, 129.4, 128.8, 126.6, 125.0. Anal. Calcd. For C₁₄H₈Br₂N₂S: C, 42.45; H, 2.04; N, 7.07; S, 8.10. Found: C, 42.27; H, 2.03; N, 7.17; S, 8.31.

3,5-Bis(3-bromophenyl)[1,2,4]thiadiazole. Solid, mp 137–140°C; ¹H NMR (500 MHz, CDCl₃) δ 8.55 (s, 1 H), 8.32 (m, 1 H), 8.21 (s, 1 H) 7.93–7.91 (m, 1 H), 7.68–7.60 (m, 2 H), 7.42–7.35 (m, 2 H); ¹³C NMR (125 MHz, CDCl₃) δ 186.7, 172.3, 134.8, 134.4, 133.4, 132.2, 131.4, 130.7, 130.3, 130.2, 126.8, 126.1, 123.4, 122.8. Anal. Calcd. For C₁₄H₈Br₂N₂S: C, 42.45; H, 2.04; N, 7.07; S, 8.10. Found: C, 42.52; H, 2.15; N, 7.01; S, 8.02.

3,5-Bis(4-fluorophenyl)[1,2,4]thiadiazole. Solid, mp 185–188°C; ¹H NMR (500 MHz, CDCl₃) δ 8.37 (m, 2 H), 8.05 (m, 2 H), 7.24–7.16 (m, 4 H); ¹³C NMR (125 MHz, CDCl₃) δ 186.9, 172.8, 165.9, 165.2, 163.9, 163.2, 130.4, 130.3, 129.6, 129.5, 116.6, 116.4, 115.8, 115.6. Anal. Calcd. For C₁₄H₈F₂N₂S: C, 61.30; H, 2.94; N, 10.21; S, 11.69. Found: C, 61.24; H, 2.92; N, 10.17; S, 11.49.

Acknowledgments. The authors are grateful to the Center of Excellence of Chemistry of University of Isfahan (CECUI) and also the Research Council of the University of Isfahan for financial support of this work.

REFERENCES AND NOTES

- [1] Castro, A.; Castaño, T.; Encinas, A.; Porcal, W.; Gil, C. *Bioorg Med Chem* 2006, 14, 1644.
- [2] Iizawa, Y.; Okonogi, K.; Hayashi, R.; Iwahi, T.; Yamazaki, T.; Imada, A. *Antimicrob Agents Chemother* 1993, 37, 100.

- [3] Martínez, A.; Fernández, E.; Castro, A.; Conde, S.; Rodríguez-Franco, I.; Baños, J. E.; Badía, A. E. *Eur J Med Chem* 2000, 35, 913.
- [4] Lanzafame, A.; Christopoulos, A. *J Pharmacol Exp Ther* 2004, 308, 830.
- [5] Song, Y. T.; Connor, D. T.; Sercel, A. D.; Sorenson, R. J.; Doubleday, R.; Unangst, P. C.; Roth, B. D.; Beylin, V. G.; Gilbertsen, R. B.; Chan, K.; Schrier, D. J.; Guglietta, A.; Bornemeier, D. A.; Dyer, R. D. *J Med Chem* 1999, 42, 1161.
- [6] (a) Kohara, Y.; Kubo, K.; Imamiya, E.; Wada, T.; Inada, Y.; Naka, T. *J Med Chem* 1996, 39, 5228; (b) Shen, L.; Zhang, Y.; Wang, A.; Sieber-McMaster, E.; Chen, X.; Pelton, P.; Xu, J. Z.; Yang, M.; Zhu, P.; Zhou, L.; Reuman, M.; Hu, Z.; Russell, R.; Gibbs, A. C.; Ross, H.; Demarest, K.; Murray, W. V.; Kuo, G.-H. *J Med Chem* 2007, 50, 3954.
- [7] (a) Ishikawa, T.; Iizawa, Y.; Okonogi, K.; Miyake, A. *J Antibiot* 2000, 53, 1053; (b) Marcinkeviciene, J.; Rogers, M. J.; Kopcho, L.; Jiang, W.; Wang, K.; Murphy, D. J.; Lippy, J.; Link, S.; Chung, T. D. Y.; Hobbs, F.; Haque, T.; Trainor, G. L.; Slee, A.; Stern, A. M.; Copeland, R. A. *Biochem Pharmacol* 2000, 60, 339.
- [8] Martínez, A.; Alonso, M.; Castro, A.; Pérez, C.; Moreno, F. *J. J Med Chem* 2002, 45, 1292.
- [9] (a) Karimian, K.; Tam, T. F.; Desilets, D.; Lee, S.; Cappelletto, T.; Li, W. U.S. Pat. 5,677,302, (1997); (b) Tam, T. F.; Leung-Toung, R.; Li, W.; Spino, M.; Karimian, K. *Mini Rev Med Chem* 2005, 5, 367.
- [10] Forlani, L.; Boga, C. *J Chem Soc Perkin Trans 2*, 2002, 768.
- [11] Yan, M.; Chen, Z.-C.; Zheng, Q.-G. *J Chem Res Synop* 2003, 618.
- [12] (a) Blotny, B. *Tetrahedron* 2006, 62, 9507; (b) Nieddu, G.; de Luca, L.; Giacomelli, G. *Synthesis* 2008, 3937.
- [13] Plechkova, N. V.; Seddon, K. R. *Chem Soc Rev* 2008, 37, 123.
- [14] Noei, J.; Khosropour, A. R. *Tetrahedron Lett* 2008, 49, 6969.
- [15] (a) Khosropour, A. R.; Khodaei, M. M.; Beygzadeh, M. *Heteroatom Chem* 2007, 18, 684; (b) Khosropour, A. R.; Khodaei, M. M.; Hoseini Jomor, S. *J Heterocycl Chem* 2008, 45, 683; (c) Khosropour, A. *Ultrason Sonochem* 2008, 15, 659.
- [16] (a) Khosropour, A. R.; Mohammadpoor-Baltork, I.; Ghorbankhani, H. *Tetrahedron Lett* 2006, 47, 3561; (b) Khosropour, A. R. *Can J Chem* 2008, 86, 264.